News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
23Andme Holding Co.
(NQ:
ME
)
0.3234
+0.0131 (+4.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about 23Andme Holding Co.
< Previous
1
2
3
4
5
6
Next >
Dow Tumbles Over 100 Points; US Initial Jobless Claims Fall Last Week
February 08, 2024
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.29% to 38,565.98 while the NASDAQ rose 0.26% to 15,796.91. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
February 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 07, 2024
Via
Benzinga
Recap: 23andMe Holding Q3 Earnings
February 07, 2024
Via
Benzinga
Earnings Scheduled For February 7, 2024
February 07, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.
Via
Benzinga
A Preview Of 23andMe Holding's Earnings
February 06, 2024
Via
Benzinga
23andMe Holding's Return On Capital Employed Overview
May 26, 2023
Via
Benzinga
Recap: 23andMe Holding Q4 Earnings
May 25, 2023
Via
Benzinga
23andMe Holding's Earnings Outlook
May 24, 2023
Via
Benzinga
Why Is Invitae (NVTA) Stock Down 75% Today?
February 05, 2024
Although genetic testing specialist Invitae forwarded a compelling idea, the lack of business substance ultimately cratered NVTA stock.
Via
InvestorPlace
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
February 05, 2024
Invitae's financial challenges as it grapples with a $1.5 billion debt burden. Explore the company's strategic options amidst potential bankruptcy, asset shedding, and cost-cutting measures.
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Troubled Biotech Company's Investigational Cancer Drug Gets Greenlighted By FDA
January 31, 2024
This development marks a significant milestone for 23andMe, a company that has been in the spotlight for security breaches in the past.
Via
Benzinga
23andMe Faces Class Action Lawsuit Over Alleged Privacy Breach Targeting Chinese And Ashkenazi Jewish Customers
January 27, 2024
23andMe faces a class-action lawsuit for a privacy breach affecting 7 million customers, particularly Chinese and Ashkenazi Jewish customers.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
The 3 Worst Stock Investments I Ever Made -- and What I Learned From Them
January 21, 2024
Not all of my investments have been winners. Here are three that went badly and the important lessons I learned from them.
Via
The Motley Fool
23andMe Reveals Hackers Accessed 'Significant Number' Of DNA Records
December 02, 2023
23andMe confirmed that hackers accessed around 14,000 customer accounts and an undisclosed number of files containing users' ancestry data.
Via
Benzinga
Topics
Hacking
Exposures
Information Security
The 3 Best Digital Health Stocks for Personalized Medicine
November 25, 2023
Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health.
Via
InvestorPlace
The Top 7 Stocks to Own During a Downturn
October 11, 2023
Investors tend to get jittery in October but these seven stocks to own during a downturn will protect your portfolio
Via
InvestorPlace
23andMe Under Siege: Hacker Reportedly Steals Millions Of Profiles In Genetic Data Heist
October 07, 2023
An unidentified hacker reportedly claims to have stolen personal genetic data from millions of 23andMe Holding Co. (NASDAQ: ME) customer accounts, sparking concerns over privacy and security.
Via
Benzinga
Topics
Hacking
Exposures
Information Security
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
September 11, 2023
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Top 5 Health Care Stocks That May Explode In Q3
September 06, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Why Olin Are Trading Lower By 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 01, 2023
Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) surged 181.1% to $3.63. TradeUP Acquisition Corp. (NASDAQ: UPTD) gained 148.5% to $18.14.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 01, 2023
Via
Benzinga
Why Dell Technologies Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
September 01, 2023
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) rose 53.4% to $0.2147 in pre-market trading after the company announced it received an Underwriting Clearance Notice for a $70 million coupon.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
August 31, 2023
Via
Benzinga
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe
August 25, 2023
Both businesses have a lot to prove.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why 23andMe Holding Stock Plummeted by 13% Today
August 09, 2023
Investors reacted sharply and not well to the company's inaugural set of fiscal 2024 earnings.
Via
The Motley Fool
3 Gene Testing Stocks to Buy Before They Take Off
June 17, 2023
The future of gene testing is bright thanks to an aging population. Here are three companies leading the industry.
Via
InvestorPlace
Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
May 23, 2023
Neither has a traditional business model, but that could be an asset for both.
Via
The Motley Fool
3 Key Biotech Trends for 2023 And Beyond
May 19, 2023
New opportunities are becoming apparent, but so are fresh risks in the biotech field.
Via
The Motley Fool
Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich … or Broke.
May 19, 2023
Explore the world of high-risk penny stocks, with their potential for significant returns, as we analyze three speculative opportunities.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.